Acceleron Pharma

Investors & Media

Press Releases

Date Title and Summary View
Toggle Summary FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions
REBLOZYL is the first and only FDA -approved erythroid maturation agent, representing a new class of therapy for these patients Approval of REBLOZYL marks the first FDA -approved treatment for anemia in beta thalassemia SUMMIT, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov.
View HTML
Toggle Summary Acceleron Announces Luspatercept Presentations at the 61st American Society of Hematology Annual Meeting
– Updated results from MEDALIST Phase 3 trial show 47.1% of patients with anemia associated with myelodysplastic syndromes treated with luspatercept achieved red blood cell transfusion independence for ≥ 8 weeks and median total duration of clinical benefit was 83.6 weeks for patients responding to
View HTML
Toggle Summary Acceleron Reports Third Quarter 2019 Operating and Financial Results
- FDA’s review of luspatercept BLA for the beta-thalassemia and lower-risk MDS indications remains ongoing - - Six clinical abstracts accepted for presentation at the 61 st American Society of Hematology (ASH) Annual Meeting - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 6, 2019-- Acceleron Pharma Inc.
View HTML
Toggle Summary Acceleron to Webcast Third Quarter 2019 Operating and Financial Results on November 6, 2019
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 29, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Wednesday, November 6, 2019 at 10:00 a.m. EST to discuss its third quarter 2019 operating and financial results.
View HTML
Toggle Summary Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy
– ACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo – – Acceleron to discontinue development of ACE-083 in facioscapulohumeral muscular dystrophy – – Topline results from the Phase 2 trial of ACE-083 in Charcot-Marie-Tooth disease expected in
View HTML
Toggle Summary Acceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial Hypertension
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 9, 2019-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (
View HTML
Toggle Summary Acceleron Reports Second Quarter 2019 Operating and Financial Results
- BLA and MAA filings of luspatercept for beta-thalassemia- and myelodysplastic syndromes-associated anemia accepted by U.S. Food and Drug Administration and European Medicines Agency , respectively - - Acceleron receives $25 million milestone payment from Celgene for luspatercept’s BLA acceptance
View HTML
Toggle Summary Acceleron to Webcast Second Quarter 2019 Operating and Financial Results on August 5, 2019
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 24, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Monday, August 5, 2019 at 5:00 p.m. EDT to discuss its second quarter 2019 operating and financial results.
View HTML
Toggle Summary Acceleron Completes Target Enrollment in the PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension
- Company now expects to report top-line results in the first quarter of 2020 - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 26, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and
View HTML
Toggle Summary Acceleron Announces Retirement of Director and Co-Founder Tom Maniatis
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 10, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that company co-founder Tom Maniatis , PhD, is
View HTML